Proveedores de Foundayo (Orforglipron) en 2026 — Clasificados y Revisados
Foundayo (orforglipron, fabricado por Eli Lilly) es la primera tableta GLP-1 oral diaria aprobada por la FDA para el manejo del peso —sin restricciones de comida ni agua, sin pluma para inyectar. Mostramos qué proveedores de telesalud y farmacias la ofrecen ahora, precios mensuales, dosis disponibles y cobertura por estado, para que sepas dónde conseguirla legítimamente.
WeightLossRankings.org se sostiene gracias a sus lectores. Cuando compras a través de enlaces en nuestro sitio, podemos ganar una comisión de afiliados. Más información
Cómo clasificamos y qué cuenta como “legítimo”
Cada proveedor en esta clasificación se puntúa contra nuestra rúbrica de seis factores[1] publicada — valor, eficacia, experiencia del usuario, confianza y seguridad, accesibilidad y soporte.
Wegovy, Zepbound, Ozempic y Mounjaro de marca están aprobados por la FDA bajo sus propios números de NDA[4][5]. La eficacia publicada de Fase 3 para semaglutida 2.4 mg (~14.9% de pérdida de peso promedio en 68 semanas) proviene del ensayo STEP 1[6], y para tirzepatida (~20.9% en dosis de 15 mg durante 72 semanas) del SURMOUNT-1[7]; el SURMOUNT-5 comparativo publicado en 2025 comparó las dos directamente[8].
La cobertura del seguro para medicamentos contra la obesidad varía ampliamente por programa de Medicaid estatal y plan comercial[9][10]. Los GLP-1 compuestos y de marca generalmente son elegibles para FSA/HSA con receta médica según la Publicación 502 del IRS[11].
Selecciones rápidas: Top 5
Reseñas detalladas
Amazon One Medical
Mejor para: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical's GLP-1 Weight Loss program is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy / Zepbound / Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery in ~3,000 US cities (expanding to 4,500 by year-end 2026) plus in-office kiosk pickup at select One Medical locations. No prior One Medical membership required to enroll. Insurance accepted; cash pay also supported. Foundayo (orforglipron) launched April 9, 2026 at $25/month with insurance + Lilly Savings Card and $149/month cash pay (manufacturer coupons auto-applied). Wegovy and Zepbound pricing varies by insurance; manufacturer savings programs (NovoCare, LillyDirect) are integrated into the checkout. Distinct from telehealth platforms that route brand-name fulfillment through Amazon Pharmacy as a backend — this is the Amazon-prescribing-side program.
Desglose de puntuación
Pros
- ✓$1/day ($25/month) with insurance and the automatically-applied Lilly manufacturer-sponsored coupon — the cheapest brand-name Foundayo channel we've seen
- ✓Same-day delivery in nearly 3,000 US cities and towns at launch, expanding to 4,500 by year-end 2026 — most aggressive delivery footprint of any GLP-1 distribution channel
- ✓In-office, licensed-pharmacist-supported kiosks at select One Medical locations let patients walk out of an appointment with their Foundayo in hand — bypasses pharmacy lines entirely
- ✓Cash-pay $5/day ($149/month) is competitive with Ro and GoodRx for the same FDA-approved brand-name product
- ✓Real-time medication availability + transparent pricing + automatic manufacturer coupon application before checkout
- ✓Has been delivering GLP-1 medications since 2021 — operational track record on cold-chain biologic logistics
- ✓24/7 access to licensed pharmacists for clinical questions
Contras
- ✗Headline $25/month Foundayo price requires both insurance coverage AND the Lilly Savings Card — uninsured patients pay the $149/month cash price
- ✗Same-day delivery is geographically gated — outside the ~3,000 cities, delivery falls back to next-day, two-day, or three-day depending on remoteness
- ✗Pricing is set by manufacturer (Lilly, Novo Nordisk) savings programs and can change at any time
- ✗Does not offer compounded semaglutide or tirzepatide — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy / Zepbound pricing is not publicly disclosed on the Amazon One Medical landing page — it depends on insurance coverage at the prescribing visit. Plan to review final pricing at checkout before committing
- ✗One Medical clinical visits accept insurance, but copays/deductibles still apply for the Scheduled Visit; cash-pay visit pricing is also disclosed on enrollment
LillyDirect Foundayo
Mejor para: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Desglose de puntuación
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Contras
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
GoodRx
Mejor para: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Desglose de puntuación
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth arm offers online GLP-1 prescriptions ($39–$70 per visit, or $19 with Gold membership) — one-stop shop for both the prescription and the discount card
Contras
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
WeightWatchers
Mejor para: Foundayo access with a structured behavior-change program
WeightWatchers offers Foundayo (orforglipron) through its Med+ program, with care delivered by the WeightWatchers Clinic affiliate medical group. Foundayo is self-pay at $149/mo for the starting dose and up to $299/mo at higher doses, billed separately from the Med+ membership ($25 first month, $74/mo after with a 12-month commitment). WW is one of the few non-pharmacy telehealth programs that lists Foundayo transparently.
Desglose de puntuación
Pros
- ✓One of the first non-pharmacy telehealth programs to list Foundayo transparently
- ✓Care delivered by WeightWatchers Clinic (affiliated medical group)
- ✓Supports all 6 Foundayo doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- ✓Publishes self-pay drug price on the product page (rare for a telehealth program)
- ✓Combines pharmacotherapy with the WW Points/behavior-change program
Contras
- ✗Med+ membership ($25 first month, $74/mo ongoing) is billed separately from the drug cost — actual out-of-pocket is higher than the listed $149/mo
- ✗State availability list not published publicly — requires eligibility quiz
- ✗Insurance coverage for Foundayo not yet available per WW's own disclosure
- ✗No compounded GLP-1 option; Foundayo only
- ✗12-month Med+ commitment required to lock the introductory $25 price
Calibrate Health
Mejor para: patients with insurance coverage who want a year-long coaching-wrap around branded Wegovy / Zepbound / Foundayo
Calibrate Health (joincalibrate.com) is a year-long metabolic-reset weight-loss program built around branded GLP-1 medication (Wegovy, Ozempic, Zepbound, or Foundayo) plus 1:1 video coaching. Program fee is $199/month with a 12-month commitment ($597 quarterly billing); medication cost is separate (~$25/month with insurance via the manufacturer savings card, otherwise standard manufacturer pricing). Distinct from 'Oxford's Medical Weight Loss / The Calibrate Clinic' already in our directory — those are unrelated entities sharing the 'Calibrate' name.
Desglose de puntuación
Pros
- ✓Year-long structured program with 1:1 video coaching, registered-dietitian support, and curriculum-based behavior-change content — deeper clinical wrap than transactional telehealth providers
- ✓$199/month program fee is competitive for a coaching-included GLP-1 program; medication co-pay drops to ~$25/month with insurance + manufacturer savings card
- ✓Branded GLP-1s only (Wegovy, Ozempic, Zepbound, Foundayo) — no compounded products, no FDA gray-zone risk
- ✓Insurance navigation team works with patients to maximize coverage; reportedly accepts most major commercial plans
- ✓Money-back guarantee tied to weight-loss outcomes (10% reduction over the program year) signals confidence in the program model
- ✓Published 3-year outcomes data ('19% mean weight loss' per Calibrate's pricing page) is more transparent than most weight-loss programs
Contras
- ✗12-month commitment with quarterly billing ($597 every 3 months) is a much higher financial lock-in than month-to-month telehealth providers — not refundable mid-program
- ✗Medication cost is on top of the $199/month program fee — cash-pay patients without insurance face full manufacturer pricing for Wegovy/Zepbound on top of the program fee, which makes the all-in cost meaningfully higher than compounded-GLP-1 telehealth providers
- ✗Insurance navigation depends on actually having coverage for branded GLP-1s for weight loss — most commercial plans still don't cover Wegovy/Zepbound for obesity without medical necessity
- ✗Program is structured around branded GLP-1s; if your insurance denies coverage and you need a more affordable channel, Calibrate is meaningfully more expensive than compounded telehealth alternatives
- ✗Distinct from 'Oxford's Medical Weight Loss (The Calibrate Clinic)' already in our directory — don't confuse the two when shopping
Ro
Mejor para: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Desglose de puntuación
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Contras
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Sesame Care
Mejor para: Brand-name GLP-1 buyers (Wegovy or Zepbound) who want LillyDirect-grade cash pricing on Zepbound vials/KwikPens or NovoCare-style first-two-month promo pricing on Wegovy without compounding risk, AND who value the ability to browse named providers with displayed prices before booking. Especially well-suited for patients in the 41 states with included lab work, patients with commercial insurance willing to pursue prior authorization for $25/mo medication access, and patients who want a single platform for weight-loss + adjacent specialties (mental health, dermatology, women's health). NOT appropriate for buyers seeking compounded GLP-1s at the $99-$249/mo budget tier (Sesame is brand-name-only for GLP-1s), buyers who require provider credentials curated and vetted by a single medical group rather than an independently-operated marketplace, or buyers in the 9 lab-excluded states unwilling to bear separate lab costs.
Multi-product telehealth MARKETPLACE (Sesame, Inc.) — fundamentally different from every other WLR-listed weight-loss provider. Sesame is NOT a stocked formulary like Hims/Henry/Ro/SkinnyRx; it is a transparent-pricing booking layer that connects patients directly with independently-owned and -operated provider practices across multiple specialties (urgent care, weight loss, mental health, dermatology, women's health, erectile dysfunction, pediatrics, prescription refills). The weight-loss vertical is branded 'Success by Sesame' and uses a subscription model: $39-$99/month for clinical care (Month-to-Month $99, 3-Month $39/mo, 6-Month $49/mo, Annual $59/mo) that covers video visits, unlimited provider messaging, follow-up visits, and lab work in most states — BUT medication is billed separately at brand-name cash-pay rates. Sesame holds a LillyDirect pharmacy partnership for Zepbound cash pricing ($299 vials at 2.5mg up to $449 at 7.5-15mg; KwikPens $299-$699) and offers Wegovy through manufacturer self-pay channels ($199/mo first two months for new self-pay patients at lowest dose, then $349/mo standard, via promo expiring 2026-06-30). Additional GLP-1 inventory: Wegovy pill ($149/mo low doses 1.5mg/4mg, $299/mo high doses 9mg/25mg), Foundayo orforglipron oral, Rybelsus oral semaglutide, plus Ozempic and Mounjaro off-label, plus non-GLP-1 weight-loss agents Saxenda, Contrave, Orlistat, and Metformin. Marketplace prescriber pool is 80+ providers spanning MD/DO/NP/FNP/PA/APRN/DNP/PMHNP/CRNP credentials. Trust signals: BBB-accredited, LegitScript-verified, lab work via Quest Diagnostics (excluded in AZ/HI/ND/NJ/NY/OK/RI/SD/WY). Multi-payout Katalys program PENDING approval ($175 weight loss, $80 ED, $140 mental health) — affiliate_url is bare https://sesamecare.com until tracking URL is issued.
Desglose de puntuación
Pros
- ✓Marketplace transparency — patients pick a specific named provider with displayed price BEFORE booking, unlike most telehealth providers where the prescribing clinician is opaque until after intake
- ✓BBB-accredited AND LegitScript-verified — trust trifecta complete (only LegitScript-verified compounding partner is missing, but Sesame's GLP-1 supply is branded via LillyDirect/NovoCare, not compounded)
- ✓LillyDirect partnership unlocks Zepbound vial and KwikPen cash pricing that matches Lilly's lowest-disclosed direct-to-consumer rates ($299 at lowest dose) — no other WLR-listed provider has this verified partnership
- ✓Wegovy self-pay promo ($199/mo for first two months, lowest dose, new self-pay only) is one of the lowest brand-Wegovy cash prices in the WLR directory through 2026-06-30
- ✓Subscription model is honest about scope — clinical care only, medication billed separately — vs. compounded-GLP-1 providers that bundle the two and obscure the medication's actual cost basis
- ✓Wegovy pill ($149/mo low doses) and Foundayo orforglipron are both stocked — Sesame is one of few providers offering both oral semaglutide AND orforglipron alongside injectables
- ✓Lab work included in subscription for 41 states (excludes AZ/HI/ND/NJ/NY/OK/RI/SD/WY)
- ✓Insurance route ($25/mo possible) is genuinely viable — providers assist with prior authorization paperwork, not just a marketing line
- ✓Cross-vertical platform means established patients can stay in-network for ED, mental health, women's health follow-ups — engagement and retention advantage
- ✓Eligibility criteria disclosed transparently (BMI 30+ or 27+ with comorbidity; standard MTC/MEN2/pancreatitis/Type 1 exclusions for GLP-1)
Contras
- ✗Marketplace model means the prescribing clinician's credentials, malpractice history, and state licensure are the INDIVIDUAL provider's, not Sesame's — quality varies provider to provider in a way that does not apply to single-physician-group competitors
- ✗States_available CANNOT be enumerated at the platform level — depends entirely on which providers in the marketplace are licensed in a given state — left empty per WLR data-discipline rule for marketplace operators
- ✗No pharmacy ownership — Sesame does not operate its own dispensing pharmacy; fulfillment is split between LillyDirect (Zepbound), NovoCare (Wegovy self-pay), and the patient's preferred retail pharmacy depending on the medication and the patient's insurance
- ✗Refund policy is restrictive: full refund only if cancellation occurs at least 3 hours prior to initial visit; no refunds for first month if initial visit occurred; previously-paid months are non-refundable
- ✗Subscription requires commitment — no genuine pay-per-visit option for the weight-loss vertical even though Sesame's broader urgent-care platform is famously per-visit
- ✗Limited-time Wegovy promo ($199/mo) gates on (a) new self-pay patient status, (b) lowest dose strength (0.25mg/0.5mg) only, (c) standard $349/mo applies after month 2 — a structurally honest disclosure but the headline price is the floor, not the average
- ✗Wegovy pill high-dose pricing ($299/mo for 9mg/25mg) is roughly 2x the low-dose price — patients titrating up the oral semaglutide ladder face material month-over-month cost increases
- ✗Zepbound KwikPen high-dose pricing ($699/mo for 10mg-15mg) approaches Lilly's list price — the LillyDirect discount narrows significantly at higher doses
- ✗Lab work excluded in 9 jurisdictions (AZ/HI/ND/NJ/NY/OK/RI/SD/WY) — patients in those states bear lab cost separately on top of the subscription
- ✗No published medical-director name or chief-medical-officer biography on the public site — marketplace by design means no single physician owns clinical governance
- ✗Katalys multi-payout offer ($175/$80/$140) is PENDING approval — affiliate_url is bare sesamecare.com until tracking URL with offer_id and aff_id parameters is issued
- ✗Existing _id 'sesame' record (added 2026-04-07) is a stale 'compounded' stub that mis-classifies Sesame's brand-only GLP-1 model — recommend deprecating that record in a follow-up pass to avoid duplicate surfacing on /compare and /best pages
Kin Meds
Mejor para: patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism)
Kin Meds (kinmeds.com) is a LegitScript-verified telehealth platform offering BOTH compounded GLP-1s (Personalized GLP-1 / semaglutide $199/mo, Personalized GLP-1+GIP / tirzepatide $249/mo) AND brand-name FDA-approved options (Wegovy injection + pill, Zepbound, Foundayo at $149/mo entry). Multi-modality menu includes Sermorelin, NAD+, Glutathione, TRT, hair growth, skin health, and sexual health. Verbatim regulatory disclosure: 'Medication is compounded and dispensed by a licensed third-party pharmacy. Kin Meds is not a state-licensed pharmacy nor a drug manufacturer.'
Desglose de puntuación
Pros
- ✓$199/mo compounded semaglutide and $249/mo compounded tirzepatide are publicly disclosed (uncommon pricing transparency)
- ✓Brand-name medications offered alongside compounded — Wegovy injection + pill, Zepbound, Foundayo all listed at $149/mo entry pricing (likely the manufacturer copay-card price for commercially insured patients)
- ✓LegitScript verification seal displayed
- ✓Verbatim regulatory disclosure clearly identifies Kin Meds as the telehealth/intake platform and the 'licensed third-party pharmacy' as the dispenser — material YMYL transparency
- ✓Multi-modality longevity menu (Sermorelin, NAD+, Glutathione) plus TRT + hair + skin + sexual health for cross-product retention
- ✓Telehealth flow (questionnaire → provider review → tailored plan → ongoing support) clearly disclosed
Contras
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Specific 'licensed third-party pharmacy' partner NOT named (verbatim disclosure acknowledges Kin Meds is NOT itself a state-licensed pharmacy)
- ✗Per-state availability NOT enumerated
- ✗$149/mo brand-name pricing for Wegovy/Zepbound/Foundayo is the entry tier — typical floors are commercial-insurance-with-savings-card; cash-pay patients should expect higher real-world costs (NovoCare $299 sema, LillyDirect $299-$449 tirz)
- ✗First-month promotional pricing NOT disclosed
- ✗Lab work + dose-titration support NOT clearly disclosed in marketing copy
- ✗Multi-product breadth (8+ categories) signals broad DTC telehealth rather than GLP-1-specialist platform
FuturHealth
Mejor para: readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up
FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added Q2 2026) plus clinician-discretionary compounded GLP-1/GIP combinations, dispensed through US-based licensed pharmacies. The platform layers digital coaching and registered-dietitian nutrition guidance on top of the medication.
Desglose de puntuación
Pros
- ✓LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- ✓Brand-name injection + oral pill GLP-1s on one platform: Wegovy injection, Wegovy oral pill, Zepbound, Mounjaro, Ozempic, Foundayo (orforglipron oral, added Q2 2026), plus clinician-discretionary compounded options
- ✓First-mover on dispensing Foundayo (orforglipron, FDA-approved April 2026) — earliest direct-to-consumer access to the new oral non-peptide GLP-1
- ✓Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
Contras
- ✗ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- ✗BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- ✗Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- ✗Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- ✗Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
AVARA Rx
Mejor para: Buyers who value supply-chain transparency and want a 50-state-confirmed cash-pay compounded GLP-1 platform with both named pharmacy (DiRx Health) and named clinical network (Beluga Health) disclosed. Strong fit for buyers comfortable with mid-tier pricing ($229 sema / $279 tirz) in exchange for the named-partner disclosure, and who want optional brand Wegovy/Zepbound/Foundayo consultations within the same platform. NOT the cheapest Beluga-network option — buyers focused on lowest cost should compare against Trimi ($99/mo sema), Coby Health ($99/mo sema), or Nalena ($149/mo). NOT for buyers needing insurance, dose-ladder transparency before purchase, or a named medical director.
AVARA Rx (avararx.com) is a nationwide DTC compounded GLP-1 telehealth platform with explicit named-pharmacy disclosure (DiRx Health, 3540 NW 56th St STE 204, Ft Lauderdale FL 33309) and explicit named-physician-network disclosure (Beluga Health, belugahealth.com) — both well above the typical DTC platform transparency floor. Mailing address is 30 N Gould Street Suite R, Sheridan, Wyoming 82801 (no operating LLC name surfaced verbatim on the homepage or FAQ — listed as 'AVARA Rx'). Products offered: Personalized GLP-1 (compounded semaglutide injection) starting at $229/mo; Personalized GLP-1/GIP (compounded tirzepatide injection) starting at $279/mo; plus brand Wegovy® injection + Wegovy® Pill + Zepbound® + Foundayo® consultations. Also markets HRT (estradiol cream/patch/tablet/vaginal cream, progesterone) and TRT (testosterone cypionate IM/cream/daily pump, hypo spray, enclomiphene) plus longevity adjuncts (NAD+, Sermorelin, Glutathione). Available in all 50 states (full list enumerated on FAQ — AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY). Insurance NOT accepted — cash-pay only. LegitScript verification badge displayed on homepage. Refund policy verbatim from FAQ: 'If our provider decides that you do not qualify for a medication, you will be refunded the cost of that medication. If the provider decides that you need a weaker formulation than what you've purchased, you will be refunded the difference.' Phone (888) 275-0960. Email info@avararx.com. Live-verified 2026-05-28.
Desglose de puntuación
Pros
- ✓Explicit named pharmacy partner disclosure — DiRx Health, 3540 NW 56th St STE 204, Ft Lauderdale FL 33309. Buyers can independently verify DiRx's licensure. Significantly above the 'licensed third-party pharmacy' generic-language floor common to DTC compounded platforms.
- ✓Explicit named clinical network disclosure — Beluga Health (belugahealth.com), the same physician-led virtual care platform used by Trimi, Healthicare, Nalena, PauseRX, Trava, and Coby Health. Buyers can research the clinical platform handling their prescriptions.
- ✓All 50 states explicitly enumerated on the FAQ — uncommon transparency vs DTC peers that say 'nationwide' without a state list
- ✓Refund policy is patient-friendly: full refund if provider disqualifies, partial refund if a weaker dose is prescribed
- ✓LegitScript verification badge displayed on homepage (claimed; independent merchant-ID lookup pending)
- ✓Pharmacy claimed to use NABP-accredited facilities (per FAQ)
- ✓Brand drug consultations (Wegovy, Wegovy Pill, Zepbound, Foundayo) available alongside compounded options — buyers can pivot between compounded and brand without switching platforms
- ✓Adjunct HRT + TRT + longevity stack (Sermorelin, NAD+, Glutathione) — broader wellness platform vs single-product GLP-1 storefronts
Contras
- ✗Operating legal entity name NOT disclosed verbatim — only 'AVARA Rx' surfaced; no LLC or corp suffix on the homepage, FAQ, or contact page. Mailing address is a Sheridan, WY registered-agent-style address (30 N Gould Street Suite R), which is a common Wyoming registered-agent shell address — does not by itself reveal the operating entity
- ✗Pricing dose ladder NOT itemized — only 'starting at $229' (sema) and 'starting at $279' (tirz) surfaced. No per-strength pricing for 0.25mg/0.5mg/1mg/1.7mg/2.4mg sema or 2.5mg/5mg/7.5mg/10mg/12.5mg/15mg tirz
- ✗LegitScript ID number NOT specified on the homepage — badge is displayed but the verifiable certification number is not surfaced, preventing direct merchant-ID lookup
- ✗Named medical director / clinical lead NOT disclosed by name (Beluga Health is the network, not a named MD)
- ✗Lab work requirements NOT specified in the FAQ — unclear whether baseline labs are required, recommended, or optional
- ✗Consultation fee structure NOT disclosed separately from medication cost
- ✗Insurance NOT accepted — cash-pay only
- ✗HSA/FSA eligibility NOT confirmed in FAQ
- ✗Pricing is mid-tier ($229 sema / $279 tirz) vs the LOW end of the DTC compounded market (Trimi $99/$125, Coby $99/$179) — buyers paying for the Beluga + DiRx transparency premium vs lower-priced Beluga-network peers
- ✗Same Beluga-clinical-network risk profile as Trimi, Healthicare, Nalena, PauseRX, Trava, Coby — if Beluga Health faces regulatory action, multiple WLR-listed platforms (including AVARA Rx) would be simultaneously affected
PauseRX
Mejor para: Buyers who value supply-chain transparency — PauseRX's explicit disclosure of the 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) + physician network (Beluga Health) + corporate entity (PauseRX, Inc.) is significantly above the typical DTC GLP-1 platform floor and lets buyers independently verify the clinical and dispensing pipeline. Strong fit for buyers comfortable with cash-pay (no insurance), async telehealth, and the restrictive no-cancellation policy. NOT a menopause-specific platform despite the brand name — buyers seeking that focus should look at Alloy, Midi Health, or Hers Menopause.
PauseRX (pauserx.com — legal entity 'PauseRX, Inc.') is a nationwide DTC compounded GLP-1 telehealth platform with explicit 503A pharmacy partner disclosure (Strive Pharmacy, 275 E Baseline Rd #104, Gilbert AZ 85233) and explicit physician-network disclosure (Beluga Health, belugahealth.com) — both significantly above the typical DTC platform transparency floor. Verbatim FDA compounded-medication disclaimer published verbatim: 'Compounded medications, where prescribed, are patient-specific and compounded in a licensed 503(A) compounding pharmacy. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.' Despite the 'Pause' name evoking menopause, the FAQ confirms the site is NOT formally positioned as menopause-specific — it emphasizes weight loss (GLP-1), performance (Sermorelin), longevity (NAD+), and antioxidants (Glutathione). Products: Personalized GLP-1 (contains semaglutide) at 'All doses at $199'/mo flat; Personalized GLP-1/GIP (contains tirzepatide) 'Starting at $249'/mo; brand Wegovy, Wegovy Pill, Zepbound, and Foundayo consultations also offered. LegitScript badge displayed (ID not specified in FAQ). Cancellation: 'Orders begin processing immediately after they are placed. As a result, we are unable to change or cancel them once submitted. Medications are not able to be returned or exchanged.' Billed when meds ship. Insurance NOT accepted. 18+ only. Async telehealth model with potential video/chat requirement in some states. Phone: (844) 917-2873. Email: hello@pauserx.com. NOT disclosed: state-by-state coverage list, named medical director, LegitScript ID number, HSA/FSA eligibility, corporate physical address. Live-verified 2026-05-20.
Desglose de puntuación
Pros
- ✓Explicit 503A pharmacy partner disclosure (Strive Pharmacy, Gilbert AZ 85233) — genuinely uncommon. Buyers can independently verify Strive Pharmacy's licensure + 503A status. Removes the typical DTC marketplace abstraction.
- ✓Explicit physician-network disclosure (Beluga Health) — buyers can research the clinical platform handling their prescriptions. Significantly above the 'certified healthcare providers' generic-language floor.
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard for compounded-product communication
- ✓Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for DTC GLP-1 platforms
- ✓$199 flat 'all doses' compounded sema pricing removes per-tier escalation
- ✓Billing at ship (not at order) reduces upfront cash exposure
- ✓LegitScript badge displayed (verification posture present even if ID not numbered in FAQ)
- ✓Adjunct longevity products (NAD+, Glutathione, Sermorelin) for buyers seeking broader wellness stack within one platform
Contras
- ✗State-by-state coverage list NOT enumerated — site claims nationwide but specific state availability requires contacting support
- ✗Cancellation policy is restrictive: 'unable to change or cancel once submitted. Medications are not able to be returned or exchanged.' — buyers who change their mind after placing an order have no recourse
- ✗Named medical director / clinical lead NOT disclosed by name despite Beluga Health network disclosure (Beluga is the network, not a named MD)
- ✗LegitScript ID NUMBER not specified in FAQ — badge is displayed but the verifiable certification number is not surfaced, preventing direct lookup
- ✗Insurance NOT accepted — cash-pay only
- ✗HSA/FSA eligibility NOT confirmed in FAQ
- ✗Corporate physical address NOT provided (only Strive Pharmacy + Beluga Health addresses)
- ✗Despite the 'Pause' brand name, the platform is NOT formally positioned as menopause/perimenopause-specific — buyers seeking menopause-focused clinical care should look at dedicated menopause platforms
- ✗Brand Wegovy + Zepbound + Foundayo are 'consultations' (not direct dispensing) — fulfillment depends on the brand-drug supply chain elsewhere
Clasificaciones relacionadas
Preguntas frecuentes
Fuentes y metodología — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.